APA (7th ed.) Citation

Jing Nie, Huina Wu, Lei Sun, Yanjiao Ding, Yepeng Luan, & Jiyong Wu. (2023). Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Jing Nie, Huina Wu, Lei Sun, Yanjiao Ding, Yepeng Luan, and Jiyong Wu. Cost-effectiveness of Fuzuloparib Compared to Routine Surveillance, Niraparib and Olaparib for Maintenance Treatment of Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Carcinoma in China. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Jing Nie, et al. Cost-effectiveness of Fuzuloparib Compared to Routine Surveillance, Niraparib and Olaparib for Maintenance Treatment of Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Carcinoma in China. Frontiers Media S.A., 2023.